We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Alizyme | AZM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.08 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.08 | 4.08 |
| Top Posts |
|---|
Posted at 26/4/2017 13:35 by fidra Noticed today that renzapride was bought by a company called endologic.Doubt it was for much as does not say.Anyone any news from liquidators? Or has anyone received any dividend! |
Posted at 01/4/2016 21:56 by elgordo This year's update from the liquidators -Section on "Shareholders": 3.5. It is anticipated that there will be sufficient funds for a distribution to be made to the Company's shareholders. As stated in the annual report of ATL, future milestone payments may be received in 2016, thus facilitating a further distribution to the Company. 3.6. Given the uncertainty surrounding potential further dividends to the Company, I am unable to provide any estimates as to the timing or quantum of a distribution to the shareholders. 3.7. There are approximately 4,500 shareholders in the Company, thus it is not cost effective to pay an interim dividend, but the position will be reassessed in one year's time. |
Posted at 27/4/2014 17:30 by mad mike I have only just come across AZM's Liquidator's reports dated 11-Feb-14 (on their web-site). For those that do not know, the important 'news' is litigation was settled last summer that had been holding up any possible realisation of assets for the benefit of shareholders.The Liquidator report says AZM shareholders will actually get something back for AZM their shares, though not immediately. Future dividend payments depend upon third parties' milestone/royalty payments. I believe there are around 217M AZM shares in issue, so it looks like every £1M of realised assets (after other creditors are paid off) would result in a shareholder payout of a little less than half a penny per share. The relevant section in the Liquidator's report is copied below. Also at the bottom there is a links to the Liquidator's Feb'04 reports:- "Shareholders [of Alizyme Plc] ~~~~~~~~~~~~ 3.5. It is anticipated that there will be sufficient funds for a distribution to be made to the Company's shareholders. As stated in the annual report of ATL, future milestone payments may be received in 2014, thus facilitating a further distribution to the Company. 3.6. Given the uncertainty surrounding potential further dividends to the Company, I am unable to provide any estimates as to the timing or quantum of a distribution to the shareholders. 3.7. There are approximately 4,500 shareholders in the Company, thus it is not cost effective to pay an interim dividend, but the position will be reassessed in one year's time." The Liquidator's 2013 annual reports for the following two companies can be found (n.b. these are different reports than those filed at Companies House):- hxxp://ww7.global3di - Alizyme Plc (the holding company that have the listed shares) - Alizyme Therapeutics Ltd (the subsidiary company holding the IPR & past activities). |
Posted at 18/2/2011 16:38 by the_doctor sorry mike, I should have said that I'd seen the tax credits stated in the docs you posted links to, but I was wondering if there was any tax asset against which profits could be offset ie. the tax losses.'I don't believe you can sell tax losses.' near enough confirms it then, thanks. I still dont quite see what represents a 3rd party and what doesnt in M&A ie. if someone reversed into AZM, could they use the tax losses? |
Posted at 18/2/2011 12:00 by mad mike AZM/ATL have already received R&D tax credits, and are already in the assets I quoted.However it you really meant past tax losses (which would be huge), I believe you can only use such tax losses against future profits. Thus a profitable company would have to reverse into AZM/ATL to realises those past tax losses. Now that AZM/ATL are in liquidation I'm doubtful if anyone can reverse into them. FYI, I don't believe you can sell tax losses. |
Posted at 18/2/2011 10:47 by the_doctor Interesting mad mike - and sad for holders of course, although something back is better than nothing!Any idea how tax credits are dealt with? ie. AZM had presumably built quite a lot up. Did that have any value, or is it not transferrable in that way? |
Posted at 18/2/2011 10:31 by mad mike The liquidator's annual reports for Alizyme Plc, and its (important subsiduary) Alizyme Therapeutics Ltd can be found here:-On a quick read (based upon current assets only), it looks like the most any Alizyme shareholder would receive is around 1.6p per share (n.b. these are my quick calculations so may be wrong, so please DYOR). My figure is just based upon £3.5M approx in current assets (after allowing for unsecured creditors), and 221M AZM shares in issue. However, even to get that payment a substaintial legal claim against the company would have to fail. Until that claim is resolved there can be no payout to unsecured creditors, let alone any payout to shareholders. Thus the claim must be substantial and likely to be in excess, of current assets i.e. greater than £3.5M. Possibly the only good news is Cetilistat has completed Phase III in Japan, & there are currently discussions about getting Market authorisation there. By good news, I'm making the unproven assumption that the current owners of Cetilistat (Norgine B.V.) could be making some payment to Alizyme if Cetilistat starts to get sold in Japan. The Annual report also announces an AGM for shareholders and creditors at 10:30am on 17/2/11, at Grant Thornton, 30 Finsbury Sq, London EC2P 2YU. Prior permission needs to be agreed before attending - see detials in Annual Report. |
Posted at 08/4/2010 00:14 by mikey34 Re mole's post.....there is a definite boiler room scam being attempted by this group....along the lines of you buy into the co which supposedly takes over AZM....HOW DO THESE GUYS SLEEP AT NIGHT??They knew exactly how many shares I held....it gave me great pleasure to listen to the entire spiel and then tell him to f---- off. |
Posted at 17/2/2010 19:27 by uptick I currently still hold 6000 AZM shares. My broker, iDealing, emailed me today with 2 options 1) To charge me £15 to send me my holding in certificated form OR 2) TO 'gift' the shares to iDealing. As AZM has delisted the possibility of a reverse T/O into the shell doesn't exist. My question, is it worth holding these in unquoted form? For example, could disposal of IP lead to any compensation? Thanks in advance. Uptick |
Posted at 17/10/2009 11:39 by rod boner On AZM's website and email alert service:Administration of Alizyme plc and Alizyme Therapeutics Limited: Update Dated: Thursday 15 October 2009 NOTICE OF CANCELLATION OF LISTING FROM THE OFFICIAL LIST Comment from Ian Carr, Joint Administrator of Alizyme plc and Alizyme Therapeutics Limited "Following my request, the Financial Services Authority has cancelled the ordinary shares in Alizyme plc - in administration, from the Official List of the London Stock Exchange effective from 14 October 2009. This step will allow me to dispose of the assets of Alizyme plc and Alizyme Therapeutics Limited for the benefit of the creditors and shareholders of the two companies. It does not affect the respective rights of the shareholders of Alizyme plc to potentially receive a dividend from the remaining net assets of Alizyme plc, if the creditors of Alizyme plc are fully repaid." ------------- Administration of Alizyme Plc and Alizyme Therapeutics Limited: Update Dated: Friday 16 October 2009 Comment from Ian Carr, Joint Administrator of Alizyme plc and Alizyme Therapeutics Limited "The Joint Administrators are pleased to announce the sale on 15 October 2009 of cetilistat, (the major product of Alizyme Therapeutics Limited) to Norgine BV. The initial consideration is £4.6m with provision for possible future revenues from a share of milestone and royalty payments. The sale should enable a dividend to be paid to Alizyme plc, the largest creditor shown in Alizyme Therapeutics Limited's Statement of Affairs, which in turn should permit a small dividend to Alizyme plc shareholders. It is not possible at this stage to be more precise as to dividend prospects for creditors and shareholders until realisations are completed and creditors claims adjudicated for both Alizyme plc and Alizyme Therapeutics Limited. The Joint Administrators will update creditors and shareholders as and when appropriate". |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
